Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
A retrospective, cross-sectional analysis demonstrated that 16.3% patients with polycythemia vera (PV) receiving hydroxyurea experienced thromboembolic events within the first year of starting treatment, which leads to increased inpatient admissions and emergency room visits and significantly higher annual healthcare costs for patients.
Journal of Managed Care & Specialty Pharmacy
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology